UHLMANN PRICE SECURITIES’s abrdn Life Sciences Investors HQL Stock Holding History

UHLMANN PRICE SECURITIES’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.63M	Buy	81,518 +3,661	+5%	+$64.7K	0.06%	45
2026 Q1	$1.27M	Buy	77,857 +1,719	+2%	+$28.7K	0.09%	54
2025 Q4	$1.28M	Buy	76,138 +2,238	+3%	+$37.6K	0.76%	32
2025 Q3	$1.15M	Buy	73,900 +12,189	+20%	+$167K	0.7%	34
2025 Q2	$790K	Sell	61,711 -9,232	-13%	-$114K	0.56%	43
2025 Q1	$900K	Buy	70,943 +3,697	+5%	+$50.1K	0.66%	37
2024 Q4	$882K	Buy	67,246 +727	+1%	+$10.5K	0.67%	37
2024 Q3	$1M	Buy	+66,519	New	+$1.01M	0.8%	28

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

UHLMANN PRICE SECURITIES's HQL Position: Q2 2026 in Review

UHLMANN PRICE SECURITIES increased its abrdn Life Sciences Investors (HQL) stake by 4.7% in Q2 2026, buying an estimated $64.7K and bringing the position to 81,518 shares worth $1.63M. The position accounts for 0.06% of the portfolio, ranked #45.

UHLMANN PRICE SECURITIES first reported a position in HQL in Q3 2024 and has held it in 8 quarters since. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

UHLMANN PRICE SECURITIES held 81,518 shares of abrdn Life Sciences Investors worth $1.63M as of Q2 2026.
UHLMANN PRICE SECURITIES bought 3,661 abrdn Life Sciences Investors shares in Q2 2026, an estimated $64.7K.
abrdn Life Sciences Investors made up 0.06% of UHLMANN PRICE SECURITIES's portfolio in Q2 2026, its #45 holding.
UHLMANN PRICE SECURITIES first reported a position in abrdn Life Sciences Investors in Q3 2024 and has held it in 8 quarters since.
83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on UHLMANN PRICE SECURITIES's 13F filing for Q2 2026, filed 24 Jul 2026.